FirstWord
79 Reports from FirstWord
-
Leveraging AI to unlock commercial insights from HCP prescribing_claims data
Leveraging AI to unlock commercial insights from HCP prescribing_claims data Electronic Medical Records (EMR) are a treasure trove of critical information for pharma, from understanding the patient journey and optimising medicines to tracking prescribing habits and unlocking competitor intelligence. ... Read More
-
Rare Disease Biomarkers and Companion Diagnostics
Rare Disease Biomarkers and Companion Diagnostics From identifying targets, influencing market access and supporting physician treatment decisions, biomarkers and companion diagnostics (CDx) are central to the success of the increasingly important rare disease sector. So, what are the latest advance ... Read More
-
Harnessing the Power of Generative AI to Improve the Customer Experience
Harnessing the Power of Generative AI to Improve the Customer Experience Few technological innovations have generated such excitement and controversy as generative AI. Advocates claim that its ability to generate high-quality text and images can revolutionise stakeholder engagement, but what of the ... Read More
-
Understanding and Communicating the Strengths and Weaknesses of RWE for Market Access
Understanding and Communicating the Strengths and Weaknesses of RWE for Market Access Real-world evidence (RWE) provides stakeholders with a more holistic view of a product’s potential and informs market access decision-making. But RWE can be based on a variety of real-world data sources, each with ... Read More
-
Leveraging the Influence of Patient Opinion Leaders and Patient Groups
Leveraging the Influence of Patient Opinion Leaders and Patient Groups How to build trusted and compliant patient relationships that deliver clinical and commercial insights The growing influence of Patient Opinion Leaders (POLs) and Patient Advocacy Groups (PAGs) can play a critical role in pharma, ... Read More
-
Driving Excellence in MSL-KOL Engagement
Driving Excellence in MSL-KOL Engagement How and where can virtual interactions improve MSL-KOL relationships? COVID-driven online MSL-KOL interactions have become the new normal, and the impact on MSL working practice has been considerable. While face-to-face interactions remain valuable, MSLs and ... Read More
-
The Role of Wearable Technology in Drug Development
The Role of Wearable Technology in Drug Development How wearable technology can take your drug development programs to the next level Advanced wearable technology is now embraced by patients, HCPs and regulators. From pre-clinical studies to post-marketing, surveillance has applications across the d ... Read More
-
Closing the Maturity Gap in Connected Health
Closing the Maturity Gap in Connected Health How to leverage insights from connected health technologies: a practical approach for pharma How can pharma benefit from the rapid growth in connected health solutions? Connected health technologies can deliver real-world data to inform the development/co ... Read More
-
Leveraging RWD and RWE to drive marketing effectiveness
Leveraging RWD and RWE to drive marketing effectiveness How to drive marketing effectiveness gains with real-world data and evidence The ability of real-world data and evidence (RWD/E) to demonstrate the value and utility of a drug is becoming increasingly influential in stakeholder decision-making. ... Read More
-
Market Access Strategies for Prescription Digital Therapeutics
Market Access Strategies for Prescription Digital Therapeutics Prescription Digital Therapeutics: Overcoming barriers and achieving market access success As the operating environment for prescription digital therapeutics (PDT) evolves, manufacturers who want success are challenged to up their market ... Read More
-
Medical Communications: Moving From Push To Pull
Medical Communications: Moving From Push To Pull How pull communications can drive better HCP engagement outcomes In a data-driven world, HCPs want to access relevant medical information at the time of their choosing on a platform of their choice. Traditional communications such as conferences and e ... Read More
-
Digital Opinion Leaders: Unlocking New Engagement Opportunities
Digital Opinion Leaders: Unlocking New Engagement Opportunities How to harness the growing influence of Digital Opinion Leaders Why should pharma engage digital opinion leaders (DOLs)? With their extensive online networks, the influence of DOLs can be wide, such as effectively engaging with underser ... Read More
-
Overcoming physician barriers to increase DTx adoption
Overcoming physician barriers to increase DTx adoption How to get physicians onboard for wider DTx adoption and use What role are healthcare professionals playing in the relatively slow uptake of DTx? While physicians are positive about the value of DTx, they remain cautious about the broader impact ... Read More
-
Innovations in medication adherence
Innovations in medication adherence New thinking on how pharma can help drive better patient medication adherence Non-adherence to medication is bad news—and it’s proving a tough nut to crack. For pharma, it can mean a loss of revenue, negative perceptions about the real-world efficacy of a drug and ... Read More
-
The ICER Effect: Payer Perspectives
The ICER Effect: Payer Perspectives How and where are ICER drug assessments influencing payer decision-making? Institute for Clinical and Economic Review (ICER) drug assessments are growing in importance and grabbing headlines in the overheated US drug market. But what does pharma need to know about ... Read More
-
Next-Generation Wearables: Applications and Opportunities for Pharma
Next-Generation Wearables: Applications and Opportunities for Pharma How–and where–can pharma leverage value from next-generation wearable technology? Powerful second-generation smart wearable devices such as hearables/earables, head-mounted displays, clothing, implantables and patches will provide ... Read More
-
Pricing and Reimbursement of Hospital Drugs in the US
Pricing and Reimbursement of Hospital Drugs in the US Brand level analysis of the latest trends in US government hospital drug funding and the companies and brands benefitting most Since the Obama reforms, Medicare Part B hospital drug expenditure has grown from $28.4 billion in 2017 to $40.1 billio ... Read More
-
Leveraging RWE to Widen Access to Therapies and Disrupt Treatment Pathways
Leveraging RWE to Widen Access to Therapies and Disrupt Treatment Pathways How RWE can disrupt treatment pathways and unlock new commercial opportunities While real-world evidence (RWE) has come to play a critical role in the pre- and post-approval drug process, it can deliver even greater value. RW ... Read More
-
Digital Health Collaborations to Accelerate Earlier Diagnosis and Treatment
Digital Health Collaborations to Accelerate Earlier Diagnosis and Treatment How digital health technology partnering can drive superior diagnosis and treatment outcomes How is pharma using digital health technology to drive improvement in the diagnosis, treatment and management of disease and when d ... Read More
-
Leveraging AI to Support Strategic Go-To-Market Decisions
Leveraging AI to Support Strategic Go-To-Market Decisions Know how AI can inform and accelerate go-to-market planning and outcomes How can Artificial Intelligence (AI) drive pharma’s go-to-market strategy? The rise of complex specialty drugs, greater payer scrutiny, and the move towards value-based ... Read More
-
Data Driven CRM in Pharma: challenges and opportunities
Data Driven CRM in Pharma: challenges and opportunities How advanced CRM systems can transform customers experience and drive commercial success Is your CRM system fit for today’s complex pharma market? Increasingly a positive experience is cited by customers as a determining factor for their purcha ... Read More
-
Digital Biomarkers: Impact on future clinical development and outcomes
Digital Biomarkers: Impact on future clinical development and outcomes How digital biomarkers could transform clinical research It is proven that digital biomarkers can accelerate and increase the efficiency of clinical drug development. Yet despite progress, the acceptance and adoption of digital b ... Read More
-
AI revolution: transforming rare disease research and development
AI revolution: transforming rare disease research and development What are the AI technologies, strategies and approaches that are really delivering value? Rare disease drug discovery and development is challenged by small patient numbers, low rates of diagnosis and geographical dispersion. But AI-e ... Read More
-
Medical Affairs Digital Transformation
Medical Affairs Digital Transformation What are the digital technologies that can really transform Medical Affairs outcomes? When it comes to Medical Affairs are the advocates of digital technology running ahead of market reality? The dash for digital in Medical Affairs is seen as critical to the fu ... Read More
-
Trends in HCP Engagement (2023)
Trends in HCP Engagement (2023) Exploring the engagement strategies that are driving successful HCP interactions To what degree has the re-emergence of face-to-face HCP engagement impacted pandemic-driven virtual/remote strategies? How will marketing budget allocations shift from HCPs to other stake ... Read More
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook